Linagliptin prevents atrial electrical and structural remodeling in a canine model of atrial fibrillation-Reference-Cited by-同舟云学术

Linagliptin prevents atrial electrical and structural remodeling in a canine model of atrial fibrillation

Published:2018-05-02 Issue:10 Volume:33 Page:1258-1265
ISSN:0910-8327
Container-title:Heart and Vessels
language:en
Short-container-title:Heart Vessels

Author:

Igarashi Tazuru^ORCID,Niwano Shinichi,Niwano Hiroe,Yoshizawa Tomoharu,Nakamura Hironori,Fukaya Hidehira,Fujiishi Tamami,Ishizue Naruya,Satoh Akira,Kishihara Jun,Murakami Masami,Ako Junya

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/article/10.1007/s00380-018-1170-0/fulltext.html

Reference21 articles.

1. Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, Maeda H, Fujisue K, Yamamoto E, Kaikita K, Hokimoto S, Jinnouchi H, Ogawa H (2013) Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J 77(5):1337–1344

2. Monami M, Ahrén B, Dicembrini I, Mannucci E (2013) Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 15(2):112–120

3. Avogaro A, de Kreutzenberg S, Fadini G (2014) Dipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protection. Curr Pharm Des 20(14):2387–2394

4. Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A (2004) Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287:E1209–E1215

5. Zeisberg M, Zeisberg EM (2015) Kidney Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin. Kidney Int 88(3):429–431

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epicardial fat and atrial fibrillation: the perils of atrial failure;EP Europace;2022-03-11

2. Circulating S100A4 as a prognostic biomarker for patients with nonparoxysmal atrial fibrillation after catheter ablation;Annals of Translational Medicine;2021-09

3. Mitochondrial Dysfunction in Atrial Fibrillation—Mechanisms and Pharmacological Interventions;Journal of Clinical Medicine;2021-05-28

4. Identification of Pivotal MicroRNAs and Target Genes Associated with Persistent Atrial Fibrillation Based on Bioinformatics Analysis;Computational and Mathematical Methods in Medicine;2021-03-06

5. Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model;Journal of the American Heart Association;2021-01-19